Accelerator Corporation Venture Capital: Cash for Up to Six Seattle Biotech Startups

SEATTLE--(BUSINESS WIRE)--Accelerator Corporation announced today that it has secured more than $22.5 million of new commitments to enable Accelerator to continue to identify, evaluate, finance, and manage emerging biotechnology opportunities. This third round of committed capital is Accelerator’s largest to date, and is led by existing investors Amgen Ventures, ARCH Venture Partners, and OVP Venture Partners, with participation by existing investor Alexandria Real Estate Equities, Inc. and new investor WRF Capital. This $22.5 million in commitments brings the total monies raised for Accelerator and Accelerator companies to more than $130 million since Accelerator’s inception in 2003. The Institute for Systems Biology will continue in its present role as the key scientific institutional anchor for Accelerator.